Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC…
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 17,601,779 shares, a decrease of 5.8% from the November 28th total of 18,695,183 shares, AnalystRatingsNetwork.com reports. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) belongs to Healthcare sector. Its weekly performance is 8.10%. On last trading…
Prosensa Holding NV (NASDAQ:RNA) was upgraded by stock analysts at KBC Securities from a “hold” rating to an “accumulate” rating in a report issued on Wednesday. The firm currently has a $11.00 price objective on the stock, up from their previous price objective of $7.00. KBC Securities’ target price would indicate a potential upside of…
Rediff.com India Limited (ADR) (NASDAQ:REDF) released its 4Q and full-year financial performance that showed somehow wanting results especially in the U.S. However, investors appeared to pay little attention to the U.S. business problems but instead looked forward to better results in the near future, just as the management promised. Rediff.com India Limited (ADR) (NASDAQ:REDF) stock…
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) presented results from a global, multi-center, open-label, comparator-controlled phase II study in patients undergoing total knee replacement surgery or total knee arthroplasty (TKA). Two doses of ISIS-FXIRx (200mg, 300mg) were compared to Sanofi’s Lovenox (enoxaparin). ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock performance was 11.26% in last session and finished the day at…
Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished…
